Clinical Trial Update: Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on ATIR donor lymphocyte preparation for haploidentical stem cell transplantation; study terminated with posted results in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoblastic Leukemia
• Lymphoma
• Multiple Myeloma
• Myelodysplastic Syndrome
• Myeloid Leukemia
• Myeloproliferative Disorders

Drugs mentioned

• ATIR

Snippet

Sponsor: Kiadis Pharma | Conditions: Myeloid Leukemia, Lymphoblastic Leukemia | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2021-01-12